Glioblastoma (GBM) is a highly malignant brain tumor. The GBM tumor mass contains a unique cell population, GBM stem cells (GBM-SCs), which possess the self-renewal, tumor initiating and tumor progression. FGF1B is the major transcriptional variant of FGF1 in GBM. In our recent study, we demonstrated the FGF1B transcript is up-regulated in self-renewing GBM cells. In order to study GBM-SCs, we developed an approach to isolate GBM-SCs by using FGF1B promoter-driven GFP reporter (F1BGFP). We showed that F1BGFP(+) GBM cells exhibit higher phosphorylation levels of FGFR and AurA than F1BGFP(-) cells, indicating the activation of FGFR and AurA. In this research highlight, we summarized the role of FGF1 signaling and AurA in tumorigenesis. In addition, we also suggested that FGF1-FGFR-AurA cascade regulates GBM-SCs, which may enable development of target-based therapy that act against the GBM-SCs.
Fibroblast growth factors (FGF) is a family of growth factors and plays an important role in developmental processes through signal FGFRs, which is a RTK family [1] . 22 FGFs have been characterized in human and mice [2] . Typically, FGFs bind to FGFR and activate several signal pathways, including Ras-Raf-MAPK, phosphatidylinositol-3 kinase-Akt, and PLC-PKC [3] . A variety of cellular events are controlled by FGFs signaling, such as cell proliferation, differentiation, migration, survival and the formation of cell shapes [4] . In postnatal tissues, FGFs have been demonstrated to be involved in in wound healing, tissue repair, angiogenesis and neurogenesis [5] [6] [7] . Due to its ability to promote cell growth, survival and angiogenesis, FGFs have been considered as a tumor promoter [3] . The observation that the prototype FGF members, FGF1 and FGF2, are overexpressed in several types of tumor and correlate with poor clinical outcome, further supports the role of FGFs in tumor development [8] . In addition, dysregulation of FGF signaling also contributes to tumor growth. Genetic alterations, including amplification, translocation and nucleotide mutation of FGFR, which lead to constitutive activation of FGF signaling, have been found in breast cancer, gastric cancer, bladder cancer, squamous cell carcinoma and glioblastoma [9] [10] [11] [12] [13] . In addition, FGF signaling has been observed to maintain the tumor
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vasculature and thus creates an efficient niche for tumor progression [14] . Therefore, FGFR has been suggested as a potential therapeutic target and valuable prognosis marker in multiple tumor types [15] [16] [17] [18] . FGF1 is the only member of FGFs that is able to bind and activate all the isoforms of FGFRs. The function of FGF1 to regulate cellular physiology in the nerve lineage cells has been extensively studied due to being highly expressed in the developmental process of nerve system. FGF1 enhances neurite outgrowth, and, notably, promotes the proliferation of neural progenitor cells in vivo and in vitro [19] [20] [21] . The human FGF1 gene spans over 120kb, and encodes four transcriptional variants,1A, 1B, 1C and 1D through alternative splicing of 5′UTR exons [22] . These four transcriptional variants are regulated by different promoter elements. Among these FGF1 variants, the FGF1B is the most abundant in nerve system and glioblastoma [23] [24] [25] [26] . Additionally, previous and our recent investigations have demonstrated that the expression of FGF1B is up-regulated during neurogenesis and self-renewal of glioblastoma stem cells (GBM-SCs) [27, 28] . The regulatory mechanism of FGF1B expression has been addressed. The expression of FGF1B appears to be under the control of 540-bp sequence upstream FGF1B promoter, which comprises the core cis-acting element for FGF1B expression [24] . Reporter system for real-time measuring the FGF1B expression is generated by assembling the -540~+31 sequence segment of FGF1B promoter with GFP coding sequence, termed F1BGFP [29] . We showed that the F1BGFP reporter signal could be detected in ependymal cells of the ventricles and in dopaminergic neurons in the adult brains of F1BGFP transgenic mice [25] . Importantly, Lee, et al. reported that F1BGFP reporter is a powerful tools for isolation of neural stem cells (NSCs) from adult and embryonic mice brain [30] . These finding, together with the highly expression levels of FGF1B in GBM tissue [26] , raising the question of whether this reporter can be used to isolate stem cells from brain tumor such as glioblastoma. Glioblastoma is a highly malignant brain tumor, and includes stem like cells (GBM-SCs), which possess sphere formation ability, a well-defined property of self-renewing neural stem cells [31] . In addition, the GBM-SCs-derived spheres retain the markers of three neural lineages (oligodendrocyte, astrocyte and neuron) [32] . Surprisingly, GBM-SCs can undergo trans-differentiation into vascular endothelial cells [33] . Most importantly, in xenograft mouse model, while GBM mass cannot be observed in NOD-SCID (non-obese diabetic, severe combined immunodeficient) mice injected with 10 5 of non-stem cells population of GBM, a relatively small amount of GBM-SCs was required to initiate GBM tumor growth [34] . Therefore, GBM-SCs is thought to be a potential target for GBM treatment and worthy to be extensively studied.
Development of methods for isolation of GBM-SCs from tumor specimen and cell lines should provide a valuable tool for GBM-SCs study. In our recent report, we showed that F1BGFP(+) GBM cells exhibit higher FGFR activation and sphere forming capacity than F1BGFP(-) cells, which in turn indicates that F1BGFP(+) GBM cells can be used for studying the behavior of GBM-SCs [28] .
The serine/threonine kinase Aurora A kinase (AurA) has been shown to participate in cell cycle progression. Upon activation, AurA is implicated in mitotic events, including centrosome maturation, centrosome separation, mitotic entry and bipolar spindle assembly [35] . The expression and activation levels of AurA is tightly regulated throughout the cell cycle in normal cells, with a peak during late G2 to M phase [36] . Although the detailed upstream regulatory signaling remains uncertain, the auto-phosphorylation of AurA Thr288 site facilitates conformation change of catalytic domain in the AurA into active form [37] .
In fact, besides its role in the cell cycle progression, the AurA is implicated in the tumor development. The dysregulation of AurA has been connected to cancer tumorigenesis and progression. Overexpressed AurA promotes centrosome amplification and aneuploidy and thus drives genetic instability [10, 38] . Amplification and overexpression of the AurA gene locus is associated with poor prognosis and chemo-/radio-resistance in several types of tumor [39] [40] [41] . Notably, inhibition of AurA by small molecules has been suggested as a potential therapy for GBM [42, 43] . Several inhibitors for AurA have been developed and evaluated in clinical trial for their potency to block tumor progress [44] . Several lines of evidence indicate that AurA contribute to the control of self-renewal of stem cells. AurA plays a key role in controlling the pluripotency of embryonic stem cells (ESCs) through phosphorylation of p53 [45] . AurA appears to maintain self-renewal ability of GBM-SCs through activation of β-catenin/Wnt Signaling [46] . In addition, AurA has been shown to participate in Drosophila neuroblast self-renewal [47] . We recently observed reduced self-renewal ability in human GBM cells, mouse ESCs and NSCs that were treated with AurA inhibitor, VX680 [28] .
We demonstrated that knockdown of FGF1 decreases sphere formation in GBM cells [48] . Recently, in our other report, blocking of FGF1/FGFR by small molecule, SU5402, results in decreased sphere forming capacity in GBM cells [28] . At the same time, FGFR blockage down-regulates AurA expression and activation. We also showed that treatment of FGF1 up-regulates AurA expression. Moreover, endogenous expression of FGF1B sensitizes GBM cells to FGF1-induced AurA expression. Based on these findings, FGF1/FGFR signaling enhances self-renewal of GBM-SCs through activation of AurA in GBM cells [28] . It has been reported that EGFR is involved in both transcriptional and translational activation of AurA expression [49, 50] . Along this line, we also found that the GBM cells with higher EGFR expression levels also demonstrated higher FGF1 induced-AurA expression levels [28] .
Our findings suggest that the FGF1-FGFR-AurA pathway (Fig. 1) is a potential therapeutic target for GBM-SCs. Thus further study is needed to understand the underlying mechanism of FGF1-induced AurA activation. We expect that our results could inspire further research in the interplay between EGFR and FGFR in regulation of AurA activation and GBM progression [28] .
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